Form 4: Suvretta Capital Boosts Benitec Biopharma Stake

Suvretta Capital Management and its affiliated funds significantly increased their beneficial ownership in Benitec Biopharma Inc. through open market purchases.

Summary

• Suvretta Capital Management, LLC, along with Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd., acquired a total of 144,223 shares of Benitec Biopharma Inc. common stock.
• The purchases occurred on December 23, 26, and 29, 2025, at weighted average prices ranging from $12.85 to $13.44 per share.
• Following these transactions, Averill Master Fund, Ltd. beneficially owns 9,700,195 shares, and Averill Madison Master Fund, Ltd. beneficially owns 1,848,156 shares.
• The reporting persons, including Aaron Cowen, are identified as both Directors and 10% Owners of Benitec Biopharma Inc.
• Kishan Mehta, a portfolio manager of Suvretta Capital, serves on the Issuer's board, establishing the Funds as directors by deputization.

Sentiment

Score: 8

Explanation: The significant open market purchases by a major institutional investor and director, Suvretta Capital Management, indicate strong confidence in the company's future prospects and valuation.

Positives

• Significant open market purchases by institutional investors and directors indicate strong confidence in Benitec Biopharma Inc.
• Increased beneficial ownership by Suvretta Capital Management and its affiliated funds, totaling 144,223 shares, demonstrates a growing stake in the company.
• The purchases were made at varying prices, with the latest transactions at $13.44 per share, suggesting continued belief in the company's value at higher price points.

Management Comments

• Aaron Cowen disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of any indirect pecuniary interest therein.
• The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Industry Context

This filing reflects an institutional investor's increased conviction in a biopharma company, a common occurrence in sectors with high growth potential and significant R&D milestones.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased confidence due to significant institutional buying by a 10% owner and director.
• Management: Potential for closer alignment with a major institutional investor's interests.

Key Dates

Recommendation

The substantial open market purchases by Suvretta Capital Management, a sophisticated institutional investor and 10% owner with board representation, signal strong conviction in Benitec Biopharma Inc.'s valuation and future prospects. Such insider buying, especially across multiple transactions and at increasing price points, often precedes positive developments or reflects a belief that the stock is undervalued, making it a compelling 'buy' signal for investors.

Keywords

Benitec Biopharma, BNTC, Suvretta Capital Management, Insider Buying, Institutional Investment, Form 4, Equity Purchase, Biopharma Stock